23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024 16:05 ET
|
23andMe, Inc.
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
March 20, 2024 07:30 ET
|
23andMe, Inc.
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of...
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
March 19, 2024 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for...
23andMe Launches New Genetic Reports on Common Forms of Cancer
March 06, 2024 07:30 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for...
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:30 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
23andMe Reports Third Quarter Fiscal 2024 Financial Results
February 07, 2024 16:01 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third...
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
January 31, 2024 07:30 ET
|
23andMe, Inc.
23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc...
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
January 30, 2024 22:12 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify...
23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
December 19, 2023 08:00 ET
|
23andMe, Inc.
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially...